NCT03916302: PE-aWARE

Pulmonary Embolism WArsaw REgistry

Recruiting now Last updated 27 October 2023

What this trial tests

trial in Acute Pulmonary Embolism in 1,500 participants. Currently enrolling.

Timeline

1 January 2008

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Medical University of Warsaw
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	1 January 2008
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across Poland

Conditions studied

• Acute Pulmonary Embolism — all drugs for Acute Pulmonary Embolism →

Sponsor

Medical University of Warsaw

Who can join

18 and older, any sex, with Acute Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Initiated in January 2008, The PE-aWARE (Pulmonary Embolism WArsaw REgistry) is an on-going single-centre prospective observational study of patients with confirmed acute pulmonary embolism (APE). Extensive data on consecutive patients with pulmonary embolism is collected and stored. The main objective is to collect and provide information on patients' characteristics, management, and outcome with the purpose of decreasing mortality in APE, the occurrence of bleeding, and the frequency of thromboembolic recurrences. Moreover, the PE-aWARE registry serves as a basis for creating predictive scores for clinicians which aid patient management. The study endpoints comprise clinically recognized (and objectively confirmed) recurrences of PE, major and minor bleeding complications classified according to the International Society on Thrombosis and Haemostasis classification, need for cardiopulmonary resuscitation or catecholamines, and death.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Plasma Troponins Identify Patients with Very Low-Risk Acute Pulmonary Embolism.
   Karolak B, Ciurzyński M, Skowrońska M, Kurnicka K, et al · · 2023 · cited 4× · PMID 36835814 · DOI 10.3390/jcm12041276
2. A Novel Doppler TRPG/AcT Index Improves Echocardiographic Diagnosis of Pulmonary Hypertension after Pulmonary Embolism.
   Dzikowska-Diduch O, Kurnicka K, Lichodziejewska B, Zdończyk O, et al · · 2022 · cited 3× · PMID 35207345 · DOI 10.3390/jcm11041072
3. Decreased Haemoglobin Level Measured at Admission Predicts Long Term Mortality after the First Episode of Acute Pulmonary Embolism.
   Justyna A, Dzikowska-Diduch O, Pacho S, Ciurzyński M, et al · · 2022 · cited 2× · PMID 36498677 · DOI 10.3390/jcm11237100
4. Elevated tricuspid peak systolic gradient with enlarged right ventricle present during acute episode of pulmonary embolism predict subsequent chronic thromboembolic pulmonary hypertension.
   Dzikowska-Diduch O, Dudzik-Niewiadomska I, Kurnicka K, Lichodziejewska B, et al · · 2025 · PMID 41456043 · DOI 10.1186/s12959-025-00818-5